We are live on
!
Find out more
BCM
Bayesian Capital Management Portfolio holdings
AUM
$156M
1-Year Est. Return
14.89%
This Fund
S&P 500
This Quarter
Est. Return
+11.62%
1 Year Est. Return
+14.89%
3 Year Est. Return
+106.87%
5 Year Est. Return
+133.82%
10 Year Est. Return
+1,146.09%
AUM
$409M
AUM Growth
-$44.1M
(-9.7%)
Cap. Flow
-$59.6M
Cap. Flow
% of AUM
-14.56%
Top 10 Holdings %
Top 10 Hldgs %
18.06%
Holding
781
New
279
Increased
97
Reduced
120
Closed
283
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$10.8M |
| 2 |
Microsoft
MSFT
|
+$7.69M |
| 3 |
TSMC
TSM
|
+$6.92M |
| 4 |
AbbVie
ABBV
|
+$6.78M |
| 5 |
NKLA
Nikola Corporation Common Stock
NKLA
|
+$6.58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$49.3M |
| 2 |
Biogen
BIIB
|
+$6.69M |
| 3 |
Accenture
ACN
|
+$6.42M |
| 4 |
Target
TGT
|
+$5.14M |
| 5 |
Walt Disney
DIS
|
+$4.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.52% |
| 2 | Consumer Discretionary | 16.31% |
| 3 | Healthcare | 16% |
| 4 | Industrials | 8.7% |
| 5 | Financials | 8.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
ATI
ATI
$29.2B
| $113K | 0.03% |
13,000
-2,155
| -14% | -$19.8K |
|
477
Annaly Capital Management
NLY
$17.4B
| $112K | 0.03% |
3,950
-4,775
| -55% | -$138K |
|
|
DVAX
478
DELISTED
Dynavax Technologies
DVAX
| $107K | 0.03% |
+24,700
| New | +$176K |
|
479
Century Aluminum
CENX
$4.54B
| $104K | 0.03% |
+14,600
| New | +$127K |
|
480
Diamondrock Hospitality Co
DRH
$2.6B
| $104K | 0.03% |
20,537
-38,315
| -65% | -$199K |
|
|
CVA
481
DELISTED
Covanta Holding Corporation
CVA
| $103K | 0.03% |
13,300
-5,700
| -30% | -$52.3K |
|
482
Liberty Latin America Class C
LILAK
$1.62B
| $102K | 0.02% |
+13,750
| New | +$110K |
|
483
Nokia
NOK
$59.3B
| $102K | 0.02% |
+25,987
| New | +$117K |
|
|
AIM
484
AIM ImmunoTech
AIM
$7.61M
| $91K | 0.02% |
+422
| New | +$105K |
|
485
Akebia Therapeutics
AKBA
$260M
| $89K | 0.02% |
+35,279
| New | +$310K |
|
486
Helix Energy Solutions
HLX
$1.49B
| $80K | 0.02% |
33,000
+6,200
| +23% | +$22.6K |
|
|
WBT
487
DELISTED
Welbilt, Inc.
WBT
| $80K | 0.02% |
+13,034
| New | +$87.8K |
|
488
Magnite
MGNI
$3.35B
| $78K | 0.02% |
+11,300
| New | +$75.5K |
|
489
KALA BIO
KALA
$15.7M
| $76K | 0.02% |
+4
| New | +$91.9K |
|
490
Amneal Pharmaceuticals
AMRX
$6.27B
| $69K | 0.02% |
+17,884
| New | +$76.5K |
|
491
Arbutus Biopharma
ABUS
$1.02B
| $64K | 0.02% |
+20,600
| New | +$62.7K |
|
|
GTT
492
DELISTED
GTT Communications, Inc.
GTT
| $57K | 0.01% |
+11,017
| New | +$65.9K |
|
493
Marathon Digital Holdings
MARA
$4.59B
| $27K | 0.01% |
+14,000
| New | +$30K |
|
494
cbdMD
YCBD
$5.57M
| $25K | 0.01% |
+35
| New | +$33.4K |
|
|
FINV
495
FinVolution Group
FINV
$949M
| $23K | 0.01% |
+12,700
| New | +$25.1K |
|
496
Chord Energy
CHRD
$7.99B
| $19K | ﹤0.01% |
+69,000
| New | +$42.2K |
|
497
Traws Pharma
TRAW
$9M
| $16K | ﹤0.01% |
+153
| New | +$37.8K |
|
|
498
Accenture
ACN
$115B
| – | – |
-29,900
| Closed | -$6.42M |
|
499
AAR Corp
AIR
$5.47B
| – | – |
-10,386
| Closed | -$215K |
|
500
Arthur J. Gallagher & Co
AJG
$66.7B
| – | – |
-13,200
| Closed | -$1.29M |
|
Similar funds
MCM
MFG
AFW
ADBIC
HSM
FWM
PIA
CCP
Bayesian Capital Management's Q3 2020 Portfolio in Review
As of Q3 2020, Bayesian Capital Management held 781 positions worth $409M, down 9.7% from $453M the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Bayesian Capital Management withdrew a net $59.6M in Q3 2020, closing 283 positions and reducing 120 holdings. Its most notable exit was Biogen, an estimated $6.69M position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Bayesian Capital Management opened a new position in Apple worth $11.5M.
- Bayesian Capital Management's largest Q3 2020 buy was Apple: 99,200 shares worth $11.5M.
- Bayesian Capital Management added most to Microsoft in Q3 2020, an estimated $7.69M increase.
- Bayesian Capital Management's biggest Q3 2020 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $49.3M.
- Bayesian Capital Management fully exited Biogen in Q3 2020, selling an estimated $6.69M.
- Bayesian Capital Management's ten largest holdings make up 18% of its $409M portfolio in Q3 2020.
- Bayesian Capital Management opened 279 new positions and closed 283 in Q3 2020.
- Bayesian Capital Management's portfolio value fell 9.7% quarter-over-quarter to $409M.
Based on Bayesian Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.